1995 Fiscal Year Final Research Report Summary
Collagen-binding activity of vitronectin in chronic liver disease.
| Project/Area Number |
06670554
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
YAMADA Sadako Tottori Univ., Fac.of Med., Research Associate, 医学部, 助手 (40150362)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Keywords | Vitronectin / Collagen-binding activity / Hepatic fibrosis / Chronic liver disease |
|---|
| Research Abstract |
The collagen-binding activity of plasma vitronectin was measured in control subjects and the patients with chronic liver disease. The plasma and liver content of vitronectin was also evaluated in these subjects. The assay of collagen-binding vitronectin was performed by an enzyme immunoassay using a monoclonal antibody to human vitronectin and type I collagen from human placenta. The standard curve of collagen-binding vitronectin is linear toward to about 2 mug/ml of vitronectin.
The total plasma concentration of vitronectin (mean <plus-minus> S.E.M.) was 261 <plus-minus> 15 mug/ml in the controls, 245 <plus-minus> 61 mug/ml in chronic persistent hepatitis, 224 <plus-minus> 14 mug/ml in chronic active hepatitis. There were no significant differences among three groups. In the liver cirrhosis and hepatocellular carcinoma groups, it was 157 <plus-minus> 14 mug/ml and 214 <plus-minus> 19 mug/ml, respectively, and both were significantly lower than that in the controls. The plasma collagen-
… More
binding vitronectin concentration was 5.6 <plus-minus> 0.5 mug/ml in the controls, 8.3 <plus-minus> 0.3 mug/ml in chronic persistent hepatitis, 8.3 <plus-minus> 0.7 mug/ml in chronic active hepatitis, 7.8 <plus-minus> 0.7 mug/ml in liver cirrhosis, and 8.2 <plus-minus> 0.5 mug/ml in hepatocellular carcinoma with cirrhosis. They were all significantly elevated compared with that in the control group. The percent collagen-binding vitronectin to total plasma vitronectin was 2.2 <plus-minus> 0.2 % in the controls, 3.90.6% in chronic persistent hepatitis, 3.9 <plus-minus> 0.3 % in chronic active hepatitis, 5.8 <plus-minus> 0.8 % in liver cirrhosis, and 4.1 <plus-minus> 0.3 % in hepatocellular carcinoma with cirrhosis, and each value was significantly higher than that in the control group. The plasma collagen-binding vitronectin also correlated with the serum levels of 7S collagen and hyaluronic acid. In chronic liver disease, serum levels of 7S collagen and hyaluronic acid significantly correlated with the hisolog
These findings suggest that vitronectin may play an important role in the progression of liver disease and/or in hepatic fibrosis through its collagen-binding domain. Less
|
